Azurity Pharmaceuticals to Acquire and Merge with Arbor Pharmaceuticals
September 24, 2021
Azurity Pharmaceuticals, majority-owned by NovaQuest Private Equity, has entered into a definitive agreement to acquire Arbor Pharmaceuticals from existing investors including JW Asset Management and KKR. The companies will merge and operate as Azurity, creating a larger specialty pharmaceuticals business with an expanded portfolio across neuroscience, cardiovascular, GI, endocrinology and institutional markets; the transaction is expected to close pending regulatory approvals.
- Buyers
- Azurity Pharmaceuticals, Inc., NovaQuest Private Equity
- Targets
- Arbor Pharmaceuticals, Inc.
- Sellers
- JW Asset Management, KKR
- Industry
- Pharmaceuticals
- Location
- Georgia, United States
- Transaction Type
- Addon
Explore More
Related Acquisitions
-
CutisPharma Acquires Silvergate Pharmaceuticals and Rebrands as Azurity Pharmaceuticals
June 12, 2019
Pharmaceuticals
CutisPharma, majority-backed by NovaQuest Private Equity (now QHP Capital), has acquired Silvergate Pharmaceuticals and the combined company will be rebranded as Azurity Pharmaceuticals. The transaction consolidates complementary specialty pharmaceutical portfolios and capabilities—combining CutisPharma’s recently launched products with Silvergate’s SG-05 pipeline submission—and is supported by debt financing arranged by Goldman Sachs Specialty Lending Group.
-
PharmaLex Acquires Arbour Group from Keystone Capital
February 12, 2020
Healthcare Services
The PharmaLex Group has acquired Arbour Group, LLC from Keystone Capital. The acquisition expands PharmaLex’s regulatory compliance, quality management and connected health capabilities and strengthens its presence in the United States.
-
Azurity Pharmaceuticals Acquires Covis Pharma
March 14, 2025
Pharmaceuticals
Azurity Pharmaceuticals has completed its acquisition of Covis Group S.à r.l. (Covis Pharma) from existing investors, making Covis a wholly owned subsidiary of Azurity. The deal expands Azurity's therapeutic portfolio across multiple complex dosage forms and broadens its global footprint, with the combined company serving 50+ countries and employing more than 800 colleagues.
-
Azurity Pharmaceuticals Acquires Slayback Pharma
September 27, 2023
Pharmaceuticals
Azurity Pharmaceuticals has completed the acquisition of Slayback Pharma LLC from existing investors including KKR and Everstone Capital, making Slayback a wholly owned subsidiary of Azurity. The deal expands Azurity's R&D and complex formulation capabilities and accelerates its pipeline for new medicine launches as part of its growth strategy under majority owner QHP Capital.
-
AmerisourceBergen Acquires PharmaLex from AUCTUS in €1.28bn Transaction
December 31, 2022
Healthcare Services
AmerisourceBergen Corporation acquired a majority stake in PharmaLex from funds advised by AUCTUS Capital Partners AG in a transaction that closed at year-end 2022 for approximately EUR 1.28 billion. PharmaLex, a Germany-headquartered provider of regulatory, clinical development and pharmacovigilance services to the life sciences industry, was grown under AUCTUS through a buy-and-build program of 38 add-ons and will expand AmerisourceBergen's global pharmaceutical solutions.
-
Optibrium Acquires BioPharmics LLC
August 31, 2023
Software
Optibrium, a Cambridge-based developer of software and AI solutions for small-molecule drug discovery, has acquired BioPharmics LLC to expand its 3D ligand- and structure-based drug design and visualisation capabilities. The acquisition brings BioPharmics' algorithms and products (including ForceGen, Surflex-Dock, eSim and QuanSA) and its founding scientists into Optibrium's StarDrop platform to strengthen 3D modelling, docking and binding-affinity prediction functionality.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.